Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 13/20 | 0.64 |
| ▸ | CA2 | P00918 | 12/20 | 0.64 |
| ▸ | CA12 | O43570 | 8/20 | 0.64 |
| ▸ | CA1 | P00915 | 8/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14926437 | 0.85 | S1PR1 (0.70) | S1PR1 | |
| SCHEMBL2774725 | 0.81 | NR1H4 (0.74) | S1PR1 | |
| SCHEMBL13873720 | 0.79 | S1PR1 (0.69) | S1PR1 | |
| SCHEMBL2806803 | 0.78 | S1PR1 (0.66) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL13875167 | 0.78 | NR1H4 (0.59) | S1PR1 | |
| SCHEMBL2771854 | 0.78 | S1PR1 (0.64) | S1PR1 | |
| SCHEMBL2775227 | 0.77 | MCL1 (0.61) | S1PR1 | |
| SCHEMBL15905727 | 0.76 | S1PR1 (0.65) | S1PR1 | |
| SCHEMBL4618138 | 0.76 | S1PR1 (0.70) | CA9CA2CA12CA1S1PR1 | |
| SCHEMBL2809563 | 0.75 | S1PR1 (0.66) | CA9CA2CA12CA1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | CA9 3283/4885CA2 2987/4885CA12 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.